VCYT — Veracyte, Inc. Stock Price, Chart & AI Report

Positive Sep 25, 2025 • 13:15 UTC Benzinga • Prnewswire

Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

Healthcare companies are advancing precision medicine through gene therapy, AI diagnostics, and innovative treatments targeting age-related conditions, with several firms making significant breakthroughs in areas like longevity biotechnology and personalized care.

AVAI QURE VCYT HUM gene therapy precision healthcare longevity biotechnology early intervention

Sentiment note

Presenting groundbreaking validation data for molecular signature predicting hormone therapy benefit in prostate cancer research

Positive Apr 8, 2025 • 08:48 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide

The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.

ADPT AMGN AZN TECH Minimal Residual Disease MRD Testing Precision Medicine Diagnostic Technologies

Sentiment note

The article mentions Veracyte, Inc. as a leading company driving innovation in the MRD testing market, suggesting their active involvement and importance in the industry.

Positive Feb 25, 2025 • 15:16 UTC Benzinga • Vandana Singh

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

Veracyte is considering selling or shutting down its French subsidiary, which generates $4 million in revenue but incurs $7 million in fixed costs, leading to a $5 million loss. An analyst believes this could be a long-term positive for the company.

VCYT Veracyte diagnostic company French subsidiary sale analyst long-term positive

Sentiment note

The article suggests that Veracyte's decision to sell or shut down its unprofitable French subsidiary could be a long-term positive for the company, as it would help reduce costs and improve overall profitability.

Positive Sep 4, 2024 • 18:30 UTC Benzinga • Zacks

Should You Continue to Retain PODD Stock in Your Portfolio Now?

Insulet's Omnipod 5 has received FDA approval for type 2 diabetes patients, expanding its market potential. However, economic uncertainty and competitive pressures remain concerns for the company.

PODD BSX VCYT Insulet Omnipod 5 FDA approval type 2 diabetes economic uncertainty

Sentiment note

Veracyte is also mentioned as a better-ranked stock in the broader medical space, suggesting a positive sentiment.

Neutral Jul 19, 2024 • 14:01 UTC Zacks Investment Research • N/A

Globus Medical (GMED) Global Sales, Innovation Aid Growth - Zacks Investment Research

Globus Medical is gaining market share in the musculoskeletal solutions space, driven by strong performance of its products. However, the company is facing challenges from global economic factors, including rising costs and inflation.

GMED HIMS VCYT HAE Globus Medical musculoskeletal solutions product launches macroeconomic factors

Sentiment note

The company's stock has declined year-to-date, but its earnings have been consistently beating estimates.

Neutral Jul 19, 2024 • 03:19 UTC Investing.com • Gurufocus

Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT) By GuruFocus - Investing.com Canada

Jens Holstein, a director at Veracyte Inc, sold 5,000 shares of the company's stock. The transaction suggests a neutral sentiment, as insider sales can be driven by various factors, including personal financial needs, rather than a negative outlook on the company's prospects.

VCYT insider sale Veracyte Inc director stock transaction

Sentiment note

The insider sale by a director does not necessarily indicate a negative sentiment towards the company. Insider transactions can be driven by various personal factors, and a single sale does not necessarily reflect the overall outlook on the company's prospects.

Unknown Jun 28, 2024 • 13:17 UTC Zacks Investment Research • Urmimala Biswas

3 Medical Instruments Picks to Navigate Industry Challenges

Deteriorating geopolitical situation and supply bottlenecks mar the prospects of the Zacks Medical Instruments industry. Yet, HOLX, MASI and VCYT are worth buying based on strategic developments and fundamentals.

HOLX MASI VCYT

Unknown Jun 26, 2024 • 09:12 UTC Zacks Investment Research • Zacks Equity Research

Zacks.com featured highlights Veracyte, Steelcase and Applied Industrial

Veracyte, Steelcase and Applied Industrial have been highlighted in this Screen of The Week article.

AIT SCS VCYT

Unknown Jun 25, 2024 • 11:40 UTC Zacks Investment Research • Santanu Roy

3 Top-Ranked Efficient Stocks to Increase Your Portfolio Returns

Invest in companies like Veracyte (VCYT), Steelcase (SCS) and Applied Industrial Technologies (AIT), as they boast higher efficiency levels.

AIT SCS VCYT

Unknown Jun 21, 2024 • 13:55 UTC Zacks Investment Research • Zacks Equity Research

Wall Street Analysts See a 37.09% Upside in Veracyte (VCYT): Can the Stock Really Move This High?

The mean of analysts' price targets for Veracyte (VCYT) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

VCYT

Unknown Jun 21, 2024 • 13:00 UTC Zacks Investment Research • Zacks Equity Research

How to Find Strong Buy Medical Stocks Using the Zacks Rank

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

VCYT

Unknown Jun 6, 2024 • 15:31 UTC Zacks Investment Research • Zacks Equity Research

Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

VCYT NARI